ELIZABETH SHELEY: Open Payments
NPI 1548875917 · OXFORD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,604 in 130 payments from 34 companies in 2025. Trend: 2023 $1,418 · 2024 $1,667 · 2025 $2,604
Food & beverage: $2,604
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 16 | $304 |
| Merck Sharp & Dohme LLC | 12 | $270 |
| E.R. Squibb & Sons, L.L.C. | 13 | $230 |
| Janssen Biotech, Inc. | 11 | $189 |
| Celgene Corporation | 8 | $167 |
| Exelixis Inc. | 6 | $117 |
| Incyte Corporation | 5 | $98 |
| PFIZER INC. | 5 | $95 |
| Gilead Sciences, Inc. | 3 | $95 |
| Lilly USA, LLC | 4 | $89 |
Products named: KEYTRUDA, REBLOZYL, ERLEADA, CABOMETYX, KISQALI, OPDIVO, Trodelvy, VERZENIO.
Industry payments across MS — which companies pay providers there.
